Surrozen, Inc./DE SRZN
We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California.
Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology in a tissue-selective manner. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling and form the foundation of our ophthalmology portfolio and research programs, which are designed to restore tissue structure and function in serious eye diseases with high unmet medical need.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $10.7M | $0 | $12.5M | $0 | — | — |
| R&D | $29.4M | $21.1M | $27.2M | $37.0M | $40.2M | $25.7M | — |
| SG&A | $16.2M | $15.1M | $15.8M | $19.8M | $14.2M | $7.1M | — |
| Total operating expenses | $45.6M | $36.2M | $45.8M | $56.8M | $54.4M | $32.8M | — |
| Operating income | -$42.1M | -$25.5M | -$45.8M | -$44.3M | -$54.4M | -$32.8M | — |
| Pre-tax income | -$242.0M | -$63.6M | -$43.0M | -$36.0M | -$54.6M | -$32.7M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$242.0M | -$63.6M | -$43.0M | -$36.0M | -$54.6M | -$32.7M | — |
| EPS, basic | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 | — | — |
| EPS, diluted | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 | — | — |
| Shares, diluted (wtd. avg.) | 7,478 | 2,933 | 2,018 | 2,314 | 24,689 | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $89.2M | $34.6M | $36.7M | $25.1M | $33.5M | $35.4M | $29.5M |
| Short-term investments | — | — | $0 | $51.1M | $68.8M | $16.4M | — |
| Receivables | $0 | $2.0M | $2.2M | $2.0M | $0 | — | — |
| Total current assets | $91.6M | $38.9M | $41.1M | $81.3M | $105.2M | $50.2M | — |
| Property, plant and equipment | $433.0K | $562.0K | $2.0M | $3.6M | $4.8M | $5.8M | — |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M | $62.1M | — |
| Accounts payable | $728.0K | $306.0K | $525.0K | $658.0K | $2.7M | $1.8M | — |
| Total current liabilities | $9.9M | $7.3M | $7.1M | $9.7M | $13.6M | $7.3M | — |
| Total liabilities | $286.5M | $69.8M | $8.1M | $13.4M | $27.5M | $14.8M | — |
| Retained earnings | -$527.3M | -$285.3M | -$221.7M | -$178.7M | -$142.6M | -$88.0M | — |
| Total equity | -$187.8M | -$21.4M | $37.9M | $76.0M | $109.7M | $47.3M | $29.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.2M | -$17.6M | -$40.4M | -$44.1M | -$48.8M | -$29.1M | — |
| Stock-based compensation | $3.8M | $4.1M | $4.4M | $4.5M | $2.3M | $635.0K | — |
| Capital expenditure | $128.0K | $26.0K | $398.0K | $728.0K | $1.3M | $874.0K | — |
| Investing cash flow | -$128.0K | -$26.0K | $51.7M | $38.3M | -$77.7M | -$15.1M | — |
| Financing cash flow | $85.1M | $16.2M | $276.0K | -$2.6M | $124.6M | $50.1M | — |
| Buybacks | — | — | $0 | $2.6M | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-119818.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $12.5M | $0 | $10.7M | $3.5M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$32.7M | -$54.6M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $240.38B | 31.2x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $196.77B | 23.4x | 2.4% |
| MRNA | Moderna, Inc. | $79.39B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $39.42B | — | — |
| BIIB | BIOGEN INC. | $37.24B | 28.7x | 2.2% |
| EXEL | EXELIXIS, INC. | $16.13B | 23.4x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.83B | 31.2x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.53B | 50.0x | 37.6% |